

Special Issue

Recent Advances in Myelodysplastic/Myeloproliferative Neoplasms

Message from the Guest Editor

The rapidly developing area of BCR-ABL negative chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) is profoundly affected by novel therapeutic and conceptual advances, as well as by the COVID-19 pandemic. In addition to the progressive nature of these entities and the risk for leukemic transformation and death due to bone marrow failure, these patients experience high cardiovascular disease burden and substantial risks of thrombosis and bleeding. Other aspects of these diseases, such as chronic renal disease and autoimmune disorders, as well as the mutual relationship with chronic systemic inflammation and cancer, are also emerging, implying that these patients might represent the human model for inflammation and cancer. The aim of this special issue is to collect articles that investigate novel and contemporary issues in the context of MPN and MDS. Manuscripts covering all aspects of research related to MPN and MDS as well as review articles focused on important novel topics are welcome.

Guest Editor

Dr. Marko Lucijanić

1. Department of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia

2. School of Medicine, University of Zagreb, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (31 March 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/109189

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).